"Biological drugs such as proteins and nucleic acids have poor bioavailability, are subject to degradation and denaturation and need to be delivered to a specific cell type and sometimes even a specific organelle to be active. Therefore, they require a drug delivery system to bring them to the target site. However, the current available drug delivery systems lack efficiency, resulting in poor efficacy of biological drugs particularly of nucleic acids. Consequently, a large number of nucleic acids have had their development discontinued, or have failed as clinical candidates. These bottlenecks pose a serious unmet medical need for pharmaceutical companies for more reliable methods of targeted drug delivery.Based on ERC research, we discovered an innovative drug delivery system based on microvesicles (MVs). We have shown that MVs have superior characteristics over current drug delivery systems for siRNA and are thus a better option for targeted delivery. Therefore, we aim to conduct a PoC study to assess the commercial potential of this proprietary system.The PoC has four goals:-To analyse the market potential of microvesicle drug delivery systems.-To assess the overall IP position on MV based drug delivery systems-To develop a product development plan to identify the commercialisation route-To manage the grant and commercialisation routeTogether this should lead to a complete package to present to venture capitalists or other strategic partners."